Company intelligence / Profile preview

Grit Studio

Zhuhai, Guangdong, Chinagritstudio.com ↗

Ownership: Private
Development stage: Other

Overview

Lead program GT101 (non-gene-engineered TIL) in pivotal Phase 2 trial for solid tumors; GT201 (gene-edited TIL with membrane-bound IL-15 complex) has IND clearance in both China and US. Early clinical data from CAR-NKT product in autoimmune patients. Multiple next-generation immunotherapies advancing through pipeline.

Therapeutic areas: OncologyImmunology
Modalities: Cell therapyGene therapymRNA-based drugsMonoclonal antibody (for TIL therapies)
Industry: Biotech

Partnerships

Vitalgen BioPharma Co., Ltd.

Beyond the preview

Go deeper on Grit Studio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Grit Studio.

Explore the full profile